In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Handheld ultrasound patent dispute

This article was originally published in The Gray Sheet

Executive Summary

SonoSite countersues General Electric July 5 in response to a patent infringement claim regarding ultrasound technology filed by GE May 15 in a U.S. District Court in Wisconsin. The patents in question involve miniaturizing ultrasound equipment to make it easily portable. SonoSite, spun off from ATL Ultrasound in 1999, offers five different "mini-laptop-sized" ultrasound systems including MicroMaxx and Titan. GE markets several compact ultrasound products of its own, including Logiq i and Vivid i, as part of its diversified imaging portfolio...

You may also be interested in...

GE/SonoSite suits settled

GE will pay the maker of the MicroMaxx point-of-care ultrasound device $21 million, as well as ongoing royalties until 2016, on U.S. hand-held ultrasound systems that weigh less than 10 pounds, under a settlement announced Oct. 19. In exchange, GE gets rights to SonoSite's U.S. Patent No. 5,722, 412. The agreement settles all pending litigation between the companies, including a GE lawsuit to invalidate the patent (1"The Gray Sheet" July 9, 2007)

EMA's Decision On Ranitidine Remaining Available Could Come At End Of April

Following the US request for ranitidine drugs to be withdrawn from the market, the European Medicines Agency says it would decide the fate of the products in the EU after wrapping up its own inquiry.

Perrigo Has Approval For Copy Of OTC Voltaren Arthritis Relief Before GSK Launches The Brand

Perrigo will launch generics of GSK's OTC Voltaren Arthritis Pain drug later in 2020 following FDA approval of its ANDA. GSK, which received FDA's OTC switch approval in February, still hasn't launched the product or indicated when it will.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts